Embryonic Ploidy Status in the Oncofertility Population

Reproductive Medicine Associates of New Jersey30 enrolled

Overview

looking at aneuploidy rates in embryos from patients who are going to or have undergone treatment for a malignancy with gonadotoxic treatment.

The study involves oncofertility patients--individuals who are undergoing or have undergone therapy for a malignancy--who are interested in pursuing or preserving fertility. In particular, it investigates chromosomal abnormalities or aneuploidy in the embryos of those individuals as compared to the general infertility population. Embryonic aneuploidy is largely due to reproductive senescence. As such the investigators will discuss oncofertility prevalence and treatment as well as reproductive senescence and assessment of embryonic aneuploidy. The study will seek to determine if there are changes in embryonic aneuploidy rates in oncofertility patients that differ from simple age related risks.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Oncology Fertility

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1.Present or past oncologic diagnosis requiring potentially gonadotoxic treatment Exclusion Criteria: 1. Oocyte banking 2. Use of oocyte donation 3. Any contraindications to undergoing in vitro fertilization or gonadotropin stimulation 4. Single gene disorder requiring more detailed embryo genetic analysis

Locations (1)

Reproductive Medicine Associates of New Jersey

Basking Ridge, New Jersey, United States

Outcomes

Primary Outcomes

embryonic aneuploidy rates

to evaluate the incidence of embryonic aneuploidy among oncofertility patients compared to the general infertility population

Time frame: 1 month

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.